Cargando…

Utility of ACMG classification to support interpretation of molecular genetic test results in patients with factor VII deficiency

BACKGROUND: The American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) have introduced an internationally shared framework for variant classification in genetic disorders. FVII deficiency is a rare inherited autosomal recessive bleeding disorder wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Alesci, Rosa Sonja, Hecking, Carola, Racké, Benjamin, Janssen, Detlev, Dempfle, Carl-Erik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10382174/
https://www.ncbi.nlm.nih.gov/pubmed/37521340
http://dx.doi.org/10.3389/fmed.2023.1220813
_version_ 1785080627189514240
author Alesci, Rosa Sonja
Hecking, Carola
Racké, Benjamin
Janssen, Detlev
Dempfle, Carl-Erik
author_facet Alesci, Rosa Sonja
Hecking, Carola
Racké, Benjamin
Janssen, Detlev
Dempfle, Carl-Erik
author_sort Alesci, Rosa Sonja
collection PubMed
description BACKGROUND: The American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) have introduced an internationally shared framework for variant classification in genetic disorders. FVII deficiency is a rare inherited autosomal recessive bleeding disorder with sparse data concerning ACMG classification. METHODS: To develop an approach which may improve the utility of molecular genetic test results, 129 patients with FVII deficiency were retrospectively assigned to six subgroups for exploratory analysis: F7 gene wildtype (group 1), ACMG 1 (benign variant) or ACMG 2 (likely benign variant), only (group 2), ACMG 3 (variant of uncertain significance) ± ACMG 1–2 heterozygous or not classified variant (group 3), ACMG 4 (likely pathogenic variant), or ACMG 5 (pathogenic variant) single heterozygous ± ACMG 1–3 single heterozygous (group 4), ACMG 4–5 homozygous or ≥2 ACMG 4–5 heterozygous or ≥1 ACMG 4–5 heterozygous plus either ACMG 1 c.1238G>A modifying variant homozygous or ≥2 ACMG 1–3 (group 5), FVII deficiency and another bleeding disorder (group 6). RESULTS: Eleven of 31 patients (35.5%) in group 5 had abnormal ISTH-BS (n = 7) and/or history of substitution with recombinant factor VIIa (n = 5) versus 4 of 80 patients (5.0%, n = 1 abnormal ISTH-BS, n = 3 substitution) in groups 1 (n = 2/22), 2 (n = 1/29), 3 (n = 0/9), and 4 (n = 1/20). Four of 18 patients (22.2%) with FVII deficiency and another bleeding disorder (group 6) had an abnormal ISTH-BS (n = 2) and/or history of substitution with recombinant factor VIIa (n = 3). CONCLUSION: Patients with a homozygous ACMG 4–5 variant or with specific combinations of heterozygous ACMG 4–5 ± ACMG 1–3 variants exhibited a high-risk bleeding phenotype in contrast to the remaining patients without another bleeding disorder. This result may serve as a basis to develop a genotype/phenotype prediction model in future studies.
format Online
Article
Text
id pubmed-10382174
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103821742023-07-29 Utility of ACMG classification to support interpretation of molecular genetic test results in patients with factor VII deficiency Alesci, Rosa Sonja Hecking, Carola Racké, Benjamin Janssen, Detlev Dempfle, Carl-Erik Front Med (Lausanne) Medicine BACKGROUND: The American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) have introduced an internationally shared framework for variant classification in genetic disorders. FVII deficiency is a rare inherited autosomal recessive bleeding disorder with sparse data concerning ACMG classification. METHODS: To develop an approach which may improve the utility of molecular genetic test results, 129 patients with FVII deficiency were retrospectively assigned to six subgroups for exploratory analysis: F7 gene wildtype (group 1), ACMG 1 (benign variant) or ACMG 2 (likely benign variant), only (group 2), ACMG 3 (variant of uncertain significance) ± ACMG 1–2 heterozygous or not classified variant (group 3), ACMG 4 (likely pathogenic variant), or ACMG 5 (pathogenic variant) single heterozygous ± ACMG 1–3 single heterozygous (group 4), ACMG 4–5 homozygous or ≥2 ACMG 4–5 heterozygous or ≥1 ACMG 4–5 heterozygous plus either ACMG 1 c.1238G>A modifying variant homozygous or ≥2 ACMG 1–3 (group 5), FVII deficiency and another bleeding disorder (group 6). RESULTS: Eleven of 31 patients (35.5%) in group 5 had abnormal ISTH-BS (n = 7) and/or history of substitution with recombinant factor VIIa (n = 5) versus 4 of 80 patients (5.0%, n = 1 abnormal ISTH-BS, n = 3 substitution) in groups 1 (n = 2/22), 2 (n = 1/29), 3 (n = 0/9), and 4 (n = 1/20). Four of 18 patients (22.2%) with FVII deficiency and another bleeding disorder (group 6) had an abnormal ISTH-BS (n = 2) and/or history of substitution with recombinant factor VIIa (n = 3). CONCLUSION: Patients with a homozygous ACMG 4–5 variant or with specific combinations of heterozygous ACMG 4–5 ± ACMG 1–3 variants exhibited a high-risk bleeding phenotype in contrast to the remaining patients without another bleeding disorder. This result may serve as a basis to develop a genotype/phenotype prediction model in future studies. Frontiers Media S.A. 2023-07-14 /pmc/articles/PMC10382174/ /pubmed/37521340 http://dx.doi.org/10.3389/fmed.2023.1220813 Text en Copyright © 2023 Alesci, Hecking, Racké, Janssen and Dempfle. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Alesci, Rosa Sonja
Hecking, Carola
Racké, Benjamin
Janssen, Detlev
Dempfle, Carl-Erik
Utility of ACMG classification to support interpretation of molecular genetic test results in patients with factor VII deficiency
title Utility of ACMG classification to support interpretation of molecular genetic test results in patients with factor VII deficiency
title_full Utility of ACMG classification to support interpretation of molecular genetic test results in patients with factor VII deficiency
title_fullStr Utility of ACMG classification to support interpretation of molecular genetic test results in patients with factor VII deficiency
title_full_unstemmed Utility of ACMG classification to support interpretation of molecular genetic test results in patients with factor VII deficiency
title_short Utility of ACMG classification to support interpretation of molecular genetic test results in patients with factor VII deficiency
title_sort utility of acmg classification to support interpretation of molecular genetic test results in patients with factor vii deficiency
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10382174/
https://www.ncbi.nlm.nih.gov/pubmed/37521340
http://dx.doi.org/10.3389/fmed.2023.1220813
work_keys_str_mv AT alescirosasonja utilityofacmgclassificationtosupportinterpretationofmoleculargenetictestresultsinpatientswithfactorviideficiency
AT heckingcarola utilityofacmgclassificationtosupportinterpretationofmoleculargenetictestresultsinpatientswithfactorviideficiency
AT rackebenjamin utilityofacmgclassificationtosupportinterpretationofmoleculargenetictestresultsinpatientswithfactorviideficiency
AT janssendetlev utilityofacmgclassificationtosupportinterpretationofmoleculargenetictestresultsinpatientswithfactorviideficiency
AT dempflecarlerik utilityofacmgclassificationtosupportinterpretationofmoleculargenetictestresultsinpatientswithfactorviideficiency